What Is Insulin?

Insulin is a peptide hormone produced by the beta cells of the pancreas in response to rising blood glucose levels. It functions as the body's primary metabolic gatekeeper — acting as a "key" that signals cells to open their glucose transporters (primarily GLUT4) and allow glucose to enter from the bloodstream to be used as fuel for cellular energy production (Wilcox, 2005).

Insulin's role extends far beyond glucose transport. It simultaneously regulates fat metabolism (suppressing lipolysis and promoting fat storage), protein synthesis, liver glycogen storage, and cellular growth signalling. It is, in effect, the body's central coordinator of energy storage versus energy burning — when insulin is high, the body is in storage mode; when insulin is low, the body shifts toward burning stored energy.

This dual role is what makes insulin dysregulation so consequential: when the insulin signalling system breaks down, the effects ripple across virtually every metabolic process in the body — from how you store fat, to how you produce energy, to how your brain processes hunger and satiety signals.

What Is Insulin Resistance?

Insulin resistance is a metabolic condition in which cells in the liver, muscles, and adipose (fat) tissue become progressively less responsive to insulin's signalling. What does insulin resistance mean at the cellular level? It means that even when insulin is present at normal or elevated levels, cells fail to adequately open their glucose transporters — glucose cannot enter efficiently, and the body's energy regulation begins to break down.

When the body senses this poor insulin response, the pancreas compensates by producing more insulin — trying to force the same metabolic effect through higher hormone levels. This compensation creates a condition called hyperinsulinemia (chronically elevated insulin levels), which often precedes any detectable change in blood sugar (Roberts et al., 2013; Kim and Reaven, 2008).

Over time, this compensatory cycle exhausts the pancreas and leads to a cascade of metabolic dysfunction: impaired glucose tolerance (high blood sugar), increased de novo lipogenesis (fat creation from sugar), visceral fat accumulation, and ultimately the constellation of conditions known as metabolic syndrome.

Critically, insulin resistance often develops years before blood sugar levels become abnormal — which is why it is frequently called a "silent" metabolic condition. Many people are insulin resistant without knowing it, because standard blood glucose tests only detect the problem after the pancreas can no longer compensate.

Insulin Resistance Symptoms: Signs to Watch For

Recognising insulin resistance symptoms early is one of the most powerful steps toward preventing metabolic disease progression. The challenge is that many signs of insulin resistance are subtle, non-specific, or attributed to other causes — which is why the condition often goes undetected for years.

The symptoms of insulin resistance span multiple body systems, reflecting the widespread disruption that impaired insulin signalling creates:

COMMON SIGNS AND SYMPTOMS OF INSULIN RESISTANCE

Insulin Resistance Symptoms in Females

Women experience several insulin resistance symptoms in females that are distinct from or more pronounced than those in men, largely because insulin resistance interacts powerfully with reproductive hormones.

The most significant female-specific manifestation is the connection between insulin resistance and PCOS (polycystic ovary syndrome). PCOS insulin resistance is estimated to affect 50–80% of women with PCOS. Excess insulin stimulates the ovaries to produce more androgens (male hormones like testosterone), which drives irregular menstrual cycles, ovulatory dysfunction, acne, hirsutism (excess hair growth), and difficulty conceiving (Purwar & Nagpure, 2022).

Other insulin resistance symptoms more prominent in females include:

• Menstrual irregularity: Hyperinsulinemia disrupts the hypothalamic-pituitary-ovarian (HPO) axis, leading to irregular, absent, or heavy periods.
• Difficulty losing weight: Women tend to store insulin-driven fat preferentially in the hip, thigh, and lower abdominal region, making insulin resistance weight loss particularly challenging. The link between weight gain and blood sugar dysregulation is especially pronounced in females.
• Fertility challenges: Insulin resistance impairs ovulation and reduces endometrial receptivity, contributing to unexplained infertility.
• Hormonal acne: Insulin-driven androgen excess triggers persistent adult acne, particularly along the jawline and chin.
• Hair thinning: Androgenic alopecia (female-pattern hair loss) is associated with insulin resistance-driven hormonal imbalance.

Understanding the relationship between insulin resistance PCOS and metabolic health is essential for women who experience these symptoms — particularly because PCOS is often diagnosed based on hormonal symptoms alone, without investigating the metabolic root cause. For more on how fructose disrupts hormonal balance during key life stages, see our guide on fructose's impact on female metabolism and perimenopause.

What Causes Insulin Resistance?

Understanding what causes insulin resistance requires looking beyond simple carbohydrate overconsumption. The insulin resistance causes are multifactorial — but emerging research strongly implicates fructose metabolism as a primary upstream driver that has been historically underappreciated. For a closer look at why traditional diets often fail to address insulin resistance, our companion article explores the root causes in more detail.

PRIMARY CAUSES AND DRIVERS OF INSULIN RESISTANCE

How Fructose Drives Insulin Resistance: The Metabolic Mechanism

Fructose is metabolised differently from glucose — it bypasses insulin regulation entirely and is processed almost exclusively in the liver. While this may seem harmless, the metabolic consequences are profound. During fructose metabolism, the enzyme fructokinase rapidly converts fructose into fructose-1-phosphate, consuming ATP (cellular energy) in an unregulated process — no feedback inhibition exists to slow it down.

This energy depletion triggers a cascade of downstream effects:

• Uric acid production: ATP depletion generates AMP, which is degraded to uric acid via purine catabolism. Elevated uric acid directly inhibits insulin signalling, promotes inflammation, and reduces nitric oxide (crucial for insulin-stimulated glucose uptake) (Zhu et al., 2014).
• Mitochondrial dysfunction: Depleted ATP impairs mitochondrial function, reducing the cell's capacity to generate energy efficiently and promoting oxidative stress (Sangwung et al., 2020).
• De novo lipogenesis: Excess fructose-1-phosphate is converted to fat through hepatic lipogenesis, depositing triglycerides directly in liver cells.
• AMPK suppression: Fructose actively suppresses AMPK — the master metabolic enzyme responsible for glucose uptake, fat oxidation, and mitochondrial function.

This combination — explored further in our article on fructose's role in the silent fatty liver epidemic — promotes non-alcoholic fatty liver disease (NAFLD), which directly impairs insulin signalling in liver cells. As liver fat increases, the body becomes less responsive to insulin — even when blood sugar levels are still in a "normal" range. This explains why insulin resistance often begins before blood sugar rises, and why people with normal fasting glucose may already be experiencing significant metabolic dysfunction (Softic et al., 2020; Hannou et al., 2018).

Insulin Resistance vs Diabetes: What's the Difference?

A common question is: "Is insulin resistance diabetes?" The answer is no — but the two are closely connected along a metabolic continuum.

Insulin resistance vs diabetes can be understood as different stages of the same underlying metabolic deterioration:

• Insulin resistance (early stage): Cells respond poorly to insulin, but the pancreas compensates by producing more. Blood sugar may remain normal or slightly elevated (fasting glucose <100 mg/dL). This stage can last 10–15 years without diagnosis.
• Prediabetes (intermediate stage): Pancreatic compensation begins to fail. Fasting blood sugar rises to 100–125 mg/dL, and/or HbA1c reaches 5.7–6.4%. At this stage, metabolic damage is already substantial — learn more about how to reverse prediabetes before it progresses.
• Type 2 diabetes (advanced stage): The pancreas can no longer produce enough insulin to compensate. Fasting blood sugar consistently exceeds 126 mg/dL, and/or HbA1c reaches 6.5%+. Beta cell function is significantly impaired. Our article on a natural approach to managing type 2 diabetes explores evidence-based strategies for this stage.

Diabetes is one of the most common consequences of insulin resistance. Fructose metabolism contributes to impaired insulin production in the pancreas — and is also associated with endogenous fructose synthesis, where your body generates fructose internally from glucose via the polyol pathway (triggered by stress, high glucose/salt intake, or dehydration). This means its metabolic effects can be felt even on a low-sugar or sugar-free diet (Lanaspa et al., 2014; Bjornstad et al., 2015).

Insulin Resistance vs Prediabetes vs Type 2 Diabetes

Insulin Resistance Test: How to Test for Insulin Resistance

Knowing how to test for insulin resistance is critical, because standard blood glucose tests often miss it. The most important principle is that insulin levels rise before glucose does — so testing insulin directly is more informative than testing glucose alone.

The primary insulin resistance test options include:

• Fasting insulin level: The most accessible screening test. Normal range is typically 2–25 μIU/mL, but research suggests that levels above 10 μIU/mL may indicate early insulin resistance. This insulin resistance blood test is inexpensive and widely available.
• HOMA-IR (Homeostatic Model Assessment): Calculated as (fasting insulin × fasting glucose) ÷ 405. A HOMA-IR score above 2.0 suggests insulin resistance; above 2.5 is considered significant. This is the most commonly used clinical assessment tool.
• Oral Glucose Tolerance Test (OGTT): Measures blood sugar and insulin at intervals after consuming a 75g glucose drink. Reveals how the body handles a glucose load and can detect impaired glucose tolerance that fasting tests miss.
• HbA1c (glycated haemoglobin): Reflects average blood sugar over 2–3 months. While useful for monitoring, HbA1c often remains normal until insulin resistance is already advanced — making it a late-stage indicator.
• Triglyceride-to-HDL ratio: A TG:HDL ratio above 3.0 is a strong surrogate marker for insulin resistance and is available on any standard lipid panel. This is one of the most cost-effective screening tools.

If you suspect insulin resistance based on symptoms — particularly fatigue, weight gain, skin changes, or family history of diabetes — requesting a fasting insulin test alongside your standard blood work is one of the most valuable early screening steps you can take.

Uric Acid: The Silent Trigger of Insulin Resistance

Uric acid is a critical — and often underestimated — driver of insulin resistance. A direct byproduct of fructose metabolism (produced when ATP depletion generates AMP, which is catabolised via the purine degradation pathway), uric acid plays a central role in the transition from metabolic stress to clinical insulin resistance.

When elevated, uric acid (Zhu et al., 2014):

• Directly inhibits insulin signalling: Uric acid impairs the insulin receptor substrate (IRS) pathway in hepatocytes, reducing the liver's response to insulin.
• Promotes inflammation: Uric acid crystals activate the NLRP3 inflammasome, driving IL-1β production and systemic inflammatory signalling.
• Induces oxidative stress: Elevated uric acid increases reactive oxygen species (ROS) generation, damaging cellular structures and impairing mitochondrial function (He et al., 2022).
• Reduces nitric oxide: Uric acid suppresses endothelial nitric oxide synthase (eNOS), reducing nitric oxide availability — which is crucial for insulin to stimulate glucose uptake in peripheral tissues.
• Impairs mitochondrial function: Hyperuricemia directly damages mitochondrial membranes and electron transport chain complexes, compounding the energy deficit created by fructose metabolism.

Improved lifestyle choices — weight loss, hydration, and decreased fructose uptake — protect against uric acid-driven metabolic damage. For a comprehensive overview, see our guide to uric acid: causes, levels & how to lower naturally.

Mitochondrial Dysfunction & ATP Depletion

Insulin resistance is not just about carbs or calories — it's about cellular energy. At its core, insulin resistance reflects a breakdown in the cell's ability to produce and manage energy efficiently — a concept explored in our article on how sugar overwhelms your cellular powerhouses. Research suggests that one of the primary causes of developing insulin resistance is ectopic lipid deposition — fat accumulating in tissues where it doesn't belong, such as the liver, pancreas, and muscle (Sangwung et al., 2020).

Decreased ATP levels (resulting from excessive fructose metabolism) prevent mitochondria — the cell's primary energy generators — from working efficiently. As mitochondrial function declines, the body's capacity to generate energy drops. The result is fat accumulation in non-adipose tissue, contributing directly to insulin resistance.

The mechanism creates a vicious cycle:

• More ectopic fat storage — particularly in liver and muscle cells that should be burning fuel, not storing it.
• More inflammation — as damaged mitochondria leak reactive oxygen species and activate inflammatory signalling.
• More insulin resistance — as inflammatory and lipid signals further impair insulin receptor function

When mitochondria are stressed from ATP depletion, they send signals that reduce the cell's ability to respond to insulin — a protective mechanism that prevents further oxidative damage but, in chronic conditions, perpetuates and deepens metabolic dysfunction. Breaking this cycle requires addressing the upstream causes of mitochondrial stress — particularly fructose overload and the resulting ATP depletion.

How to Reverse Insulin Resistance

Can insulin resistance be reversed? Yes — particularly when identified early and addressed at the metabolic root, rather than simply managing blood sugar numbers. Effective insulin resistance treatment requires addressing the underlying drivers — fructose metabolism, mitochondrial dysfunction, inflammation, and ectopic fat — not just reducing carbohydrate intake. Combining dietary changes with targeted strategies to stimulate fat loss can accelerate reversal.

Evidence-based strategies for how to reverse insulin resistance include:

HOW TO TREAT INSULIN RESISTANCE: EVIDENCE-BASED STRATEGIES

Insulin Resistance Diet: What to Eat and What to Avoid

An effective insulin resistance diet focuses not just on reducing carbohydrates, but specifically on reducing the metabolic triggers that drive insulin resistance at the cellular level — particularly concentrated fructose, refined sugars, and high-glycemic processed foods.

The core principles of an insulin resistance diet:

• Prioritise whole, unprocessed foods: Vegetables, legumes, nuts, seeds, whole grains, lean proteins, and healthy fats form the foundation.
• Emphasise fibre: Soluble fibre slows glucose absorption and feeds beneficial gut bacteria. Target 25–35g daily from whole food sources.
• Include healthy fats: Olive oil, avocado, nuts, and fatty fish (omega-3s) improve insulin sensitivity and reduce inflammation.
• Choose low-glycemic carbohydrates: Steel-cut oats, sweet potatoes, quinoa, and berries over white bread, rice, and refined cereals.
• Adequate protein: Protein at every meal helps stabilise blood sugar and supports satiety signalling.

Foods to avoid with insulin resistance:

• Sugary beverages (soft drinks, fruit juice, sweetened coffees, energy drinks)
• High-fructose corn syrup in processed foods (check labels on sauces, bread, cereals)
• Refined carbohydrates (white bread, pastries, crackers)
• Ultra-processed snack foods (chips, biscuits, granola bars)
• Excess alcohol (drives hepatic fat accumulation)
• Dried fruit and agave nectar (concentrated fructose sources)

Intermittent fasting for insulin resistance has shown promising results in research. Time-restricted eating (typically 16:8 or 14:10 schedules) can improve insulin sensitivity by allowing insulin levels to fall during fasting periods, giving cells time to recover their receptor sensitivity. The best intermittent fasting schedule for insulin resistance is one that is sustainable for the individual — consistency matters more than the specific window. The ultimate goal is developing metabolic flexibility — the ability to efficiently handle dietary sugar rather than being locked into chronic storage mode.

Insulin Resistance Diet: Foods to Include vs Avoid

Supplements for Insulin Resistance

Alongside diet and exercise, targeted insulin resistance supplements can address specific metabolic pathways that lifestyle changes alone may not fully resolve. The most evidence-based supplements to reverse insulin resistance target AMPK activation, fructose metabolism, uric acid, mitochondrial function, and inflammation.

BEST SUPPLEMENTS FOR INSULIN RESISTANCE

Metformin for Insulin Resistance

Metformin for insulin resistance is the most commonly prescribed pharmaceutical intervention. Like berberine, metformin activates AMPK via partial inhibition of mitochondrial Complex I — suppressing hepatic glucose production, improving peripheral insulin sensitivity, and modestly reducing weight.

Insulin resistance medication is typically considered when lifestyle interventions alone are insufficient to control metabolic markers, particularly in prediabetic or diabetic ranges. Metformin is the first-line pharmacological choice due to its established safety profile, cardiovascular benefits, and low hypoglycemia risk.

However, it's important to understand that metformin addresses the downstream consequences of insulin resistance (excess hepatic glucose production) rather than the upstream metabolic triggers (fructose-driven liver fat accumulation, uric acid, AMPK suppression). This is why combining pharmaceutical approaches with root-cause metabolic strategies — dietary fructose reduction, targeted supplementation, and lifestyle modification — may offer more comprehensive metabolic improvement than medication alone.

Is Insulin Resistance Purely Bad? An Evolutionary Perspective

While insulin resistance is often portrayed as a metabolic malfunction, emerging research suggests it can be understood as an initially protective adaptation to cellular energy stress (Barzilai and Ferrucci, 2012). When cells experience low ATP and high oxidative stress — conditions strongly linked to excessive fructose metabolism — reducing their sensitivity to insulin is a way of managing energy allocation (Nolan et al., 2015).

By making it harder for glucose to enter certain cells, the body can:

• Prevent further oxidative damage — reducing the metabolic burden on already-stressed cells.
• Prioritise energy delivery to the most critical tissues — such as the brain and heart.
• Preserve glucose supply for insulin-independent tissues — the brain, red blood cells, and immune cells.

Evolutionary hypotheses suggest this response once promoted fat storage for survival during food scarcity or illness. In those contexts, fat was safely stored in adipose tissue, sparing vital organs from ectopic fat accumulation (Soeters and Soeters, 2012).

In the modern world — with constant access to calorie-dense foods, year-round sugar availability, and minimal environmental stress — these protective mechanisms remain switched on unnecessarily. Persistent drivers such as fructose-induced ATP depletion, uric acid buildup, and mitochondrial overload turn what was once an acute survival advantage into a chronic driver of metabolic disease. This reframes insulin resistance not as the primary defect, but as a compensatory step in a deeper chain of metabolic events.

The LIV3 Perspective on Insulin Resistance

At LIV3 Health, we believe insulin resistance is not simply a glucose problem — it's a fructose metabolism problem. By understanding and supporting the pathways involved — especially those driven by fructokinase and uric acid — we aim to restore the conditions under which cells can regain insulin sensitivity.

The mechanism underlying SugarShield fructose control is liposomal delivery of active ingredients: luteolin — a flavonoid found in various fruits and vegetables that enhances anti-inflammatory and antioxidant defences and has been shown to directly modulate fructokinase activity — and tart cherry extract, rich in anthocyanins, which supports metabolic health by lowering inflammation and uric acid. By targeting fructokinase, we aim to address the upstream trigger of the metabolic cascade that leads to insulin resistance — restoring cellular energy and supporting metabolic health.

This approach complements downstream interventions like berberine (AMPK reactivation) and lifestyle modifications (diet, exercise, sleep). Together, they address both the cause and consequence of fructose-driven metabolic dysfunction — supporting the metabolic flexibility needed for long-term health.

Recognising and addressing insulin resistance early is one of the most powerful steps you can take to reclaim your metabolic health. A healthy lifestyle — nutritious diet choices, regular physical activity, quality sleep, and adequate hydration — remains the foundation. Targeted metabolic support builds on that foundation to address the pathways that lifestyle alone may not fully reach.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Summary

Insulin resistance is a foundational metabolic condition that underpins many of the most prevalent chronic diseases — from type 2 diabetes and cardiovascular disease to PCOS, NAFLD, and metabolic syndrome. It develops silently, often years before blood sugar levels become abnormal, and affects an estimated 40% of US adults.

The evidence increasingly points to fructose metabolism as a primary upstream driver — through hepatic fat accumulation, AMPK suppression, uric acid generation, and mitochondrial dysfunction. Understanding this connection shifts the focus from simply managing blood sugar to addressing the root metabolic causes.

Insulin resistance can be reversed — particularly when caught early. The most effective approach combines an insulin resistance diet rich in whole foods and low in concentrated fructose, regular exercise (both aerobic and resistance), quality sleep, stress management, and targeted supplements for insulin resistance that address specific metabolic pathways.

At LIV3 Health, we believe that educating people on the mechanisms behind insulin resistance — and the central role of fructose metabolism — is the first step toward meaningful metabolic health improvement.

References

• Barzilai, N. & Ferrucci, L. (2012). Insulin Resistance and Aging: A Cause or a Protective Response? The Journals of Gerontology: Series A, 67(12), 1329–1331.
• Bjornstad, P., Lanaspa, M. A., Ishimoto, T., et al. (2015). Fructose and uric acid in diabetic nephropathy. Diabetologia, 58(9), 1993–2002.
• Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018). Fructose metabolism and metabolic disease. The Journal of Clinical Investigation, 128(2), 545–555.
• He, F., Wang, M., Zhao, H., et al. (2022). Autophagy protects against high uric acid-induced hepatic insulin resistance. Molecular and Cellular Endocrinology, 547, 111599.
• Kim, S. H. & Reaven, G. M. (2008). Insulin Resistance and Hyperinsulinemia: You can't have one without the other. Diabetes Care, 31(7), 1433–1438.
• Lanaspa, M. A., Ishimoto, T., Li, N., et al. (2014). Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. Journal of the American Society of Nephrology, 25(11), 2526–2538.
• Lebovitz, H. E. (2001). Insulin resistance: definition and consequences. Experimental and Clinical Endocrinology & Diabetes, 109(2), 135–148.
• Nolan, C. J., Ruderman, N. B., Kahn, S. E., et al. (2015). Insulin resistance as a physiological defense against metabolic stress. Diabetes, 64(3), 673–686.
• Purwar, A. & Nagpure, S. (2022). Insulin Resistance in Polycystic Ovarian Syndrome. Cureus, 14(10), e30351.
• Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013). Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Comprehensive Physiology, 3(1), 1–58.
• Sangwung, P., Petersen, K. F., Shulman, G. I., & Knowles, J. W. (2020). Mitochondrial Dysfunction, Insulin Resistance, and Potential Genetic Implications. Endocrinology, 161(4), bqaa017.
• Soeters, M. R. & Soeters, P. B. (2012). The evolutionary benefit of insulin resistance. Clinical Nutrition, 31(6), 1002–1007.
• Softic, S., Stanhope, K. L., Boucher, J., et al. (2020). Fructose and hepatic insulin resistance. Critical Reviews in Clinical Laboratory Sciences, 57(5), 308–322.
• Wilcox, G. (2005). Insulin and Insulin Resistance. The Clinical Biochemist Reviews, 26(2), 19–39.
• Zhu, Y., Hu, Y., Huang, T., et al. (2014). High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochemical and Biophysical Research Communications, 447(4), 707–714.